Use of topiramate (topamax) in a subgroup of migraine-vertigo patients with auditory symptoms.
Five-three percent of the patients who suffer from migraine present severe incapacity and need rest in bed. If we add to this the incapacity produced by vertigo, then the quality of life of these patients is seriously affected. Migraine/Vertigo (MV) should be another criterion in the selection of preventive treatment even when other criteria are not fulfilled. Auditory symptoms may accompany MV. We treated 10 patients with Topiramate in an open trial, twice a day, with an average dose of 100 mg/day. The treatment period for these patients ranges between 6 and 16 months, with a mean of 9. As of today, all patients present no crisis. Regarding auditory symptoms, all the patients referred that they were stabilized. The effect began quickly, from the first month in most patients as it has been reported in other studies.
Carmona
Sergio
S
Instituto de Neurociencias de Buenos Aires (INEBA), Buenos Aires, Argentina. scarmona@arnet.com.ar
Settecase
Norma
N
D000328:Adult; D000368:Aged; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006311:Hearing Disorders / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000150:complications / Q000188:drug therapy*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D000077236:Topiramate; D014717:Vertigo / Q000150:complications / Q000188:drug therapy*
D018696:Neuroprotective Agents; D000077236:Topiramate; D005632:Fructose